Novartis AG (NVS)

86.96
0.40 0.46
NYSE : Health Technology
Prev Close 86.56
Open 85.93
Day Low/High 85.92 / 87.38
52 Wk Low/High 74.97 / 96.31
Volume 4.07M
Avg Volume 1.82M
Exchange NYSE
Shares Outstanding 2.53B
Market Cap 219.04B
EPS 5.50
P/E Ratio 16.15
Div & Yield 1.84 (2.11%)

Latest News

Novartis Tops Estimates With Third-Quarter Results

We think the quarter will gain the proper recognition as time progresses.

Novartis Posts Third-Quarter Earnings Beat on Strong Drug Sales

Novartis Posts Third-Quarter Earnings Beat on Strong Drug Sales

Novartis beats analysts' third-quarter earnings expectations on a double-digit increase in sales.

Adding to Novartis Shortly After the Bell

We think the quarter looks strong across the board.

A Look Into 4 Companies That Report Earnings This Week

Our focus today is on Novartis, Caterpillar, Microsoft and Lam Research.

Video: Jim's Daily Rundown for Monday

Jim discusses trade with China, what to think of Novartis before tomorrow morning's earnings release, an Apple price target increase at Raymond James and more!

Following Up on Kohl's, Caterpillar and Johnson & Johnson

Let's circle back to last Friday's stock-driving headlines.

Weekly Roundup

Markets tread water near all-time highs as earnings season gets underway.

New Disclosures Send Viacom-CBS Modestly Lower

This discounted value and the potential benefits of the merger/integration catalyst is why we continue view this stock as a hold despite its recent struggles.

Johnson & Johnson Reports Third Quarter Top and Bottom Line Beat

This strong beat and raise result should spark renewed buying interest in the stock.

Weekly Roundup

Markets finish strong on optimism U.S. trade tensions with China may be easing.

Johnson & Johnson Falls Wednesday on Risperdal Verdict

It is disheartening to see a new litigation headline pop up, but we do not expect this risk to have the staying power of talc and opioids.

Weekly Roundup

A volatile week ends with heightened expectations for at least one more rate cut from the Fed.

We Rallied, but the Stats Weren't So Hot

Breadth was crummy, the Russell lagged and the number of stocks making new lows on a 10-day moving average shows no sign of turning down yet.

September ADP Employment Report Missed Expectations

The ADP numbers... are beginning to show signs of a slowdown as employers grow more cautious when it comes to hiring activity.

Adding to a Pharmaceutical Name and Upgrading a Position

With the market expected to continue Tuesday's weak ISM PMI-driven woes, we are in position to do some buying at newly discounted prices.

Weekly Roundup

Markets buffeted by impeachment turmoil and shift away from high-multiple growth names.

Video: Jim's Daily Rundown for Thursday

Jim talks about his interview with Twilio CEO Jeff Lawson, Facebook amid the DoJ's antitrust probe and answers a club member's question!

Amgen Looks Attractive After Its Recent Pullback

Amgen Looks Attractive After Its Recent Pullback

Amgen's AMG 510 phase 1 results helped change the narrative around the stock, but that was just the beginning.

Weekly Roundup

Markets traded mostly flat this week in spite of Saudi oil attacks, and a Fed rate cut, only turning sour on Friday on signs of renewed U.S. trade tensions with China.

Adding to a Pharmaceutical Position

We want to nibble on Novartis, which is barely reacting to company-specific positive news.

Video: Jim's Daily Rundown for Tuesday

Jim discusses Novartis, Home Depot, and more!

Stay on Top of Your Game: Cramer's 'Mad Money' Recap (Friday 9/13/19)

Stay on Top of Your Game: Cramer's 'Mad Money' Recap (Friday 9/13/19)

Jim Cramer says investors need to stay vigilant, despite recent market gains. He's got your game plan for next week.

Trex, Enphase Energy, Alcon: 'Mad Money' Lightning Round

Trex, Enphase Energy, Alcon: 'Mad Money' Lightning Round

Jim Cramer takes a look at Trex, Enphase Energy, Alcon, Rite Aid, Tallgrass Energy and more.

Markets Have a Strong Week on Sector Rotation, Reviving Chip Stocks

Easing trade tensions and steepening yield curve add to bulls' optimism.

Adding to a Pharmaceutical Name While Taking Gains in a Semi

We will buy more Novartis shares and trim our Lam Research position.

NATIONALLY RANKED ROSEN LAW FIRM Continues To Investigate Securities Claims Against Novartis AG; ENCOURAGES INVESTORS WITH LOSSES IN EXCESS OF $100K TO CONTACT THE FIRM  - NVS

NATIONALLY RANKED ROSEN LAW FIRM Continues To Investigate Securities Claims Against Novartis AG; ENCOURAGES INVESTORS WITH LOSSES IN EXCESS OF $100K TO CONTACT THE FIRM  - NVS

Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business...

Tech Stocks Lag, Health Care Shakes Up and Apple's in TV

Tuesday is a big day as the rotation in the markets continues -- putting the likes of Salesforce.com on sale; pharma gets jitters over political climate; and Apple aims at Netflix and co.

Two Tuesday Buys

We will add to our Novartis and Twilio positions this morning.

TheStreet Quant Rating: A- (Buy)